A multicentre, open, parallel study to evaluate the effect of itacitinib in patients with graft‐versus‐host disease
Latest Information Update: 18 Jan 2021
Price :
$35 *
At a glance
- Drugs Itacitinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics
- 12 Jan 2021 Results (n=22) published in the Journal of Clinical Pharmacology
- 13 Mar 2020 New trial record
- 09 Mar 2020 Results published in the Journal of Clinical Pharmacology